| Literature DB >> 36071498 |
Wilson de Melo Cruvinel1, Luis Eduardo Coelho Andrade2, Alessandra Dellavance3,4, Antônio Carlos Ximenes5, Carlos David Araújo Bichara6, Cristóvão Luis Pitangueira Mangueira7, Eloísa Bonfá8, Fabiano de Almeida Brito9,10, Henrique Ataíde Mariz11, Lisiane Maria Enriconi Dos Anjos12, Sandra Gofinet Pasoto13, Valeria Valim14, Wilton Ferreira Silva Dos Santos15, Clayson Moura Gomes16, Roberpaulo Anacleto Neves16, Paulo Luiz Carvalho Francescantonio16.
Abstract
BACKGROUND: The VI Brazilian Consensus on Autoantibodies against HEp-2 cells for determination of autoantibodies against cellular constituents on HEp-2 cells was held on September, 2019, in Fortaleza (CE, Brazil). The guidelines in this edition were formulated by the group of Brazilian experts discussing the classification of complex patterns, the classification of the nuclear discrete dots (few and multiple), the identification of the discrete fine speckled pattern (AC-4a) and improvements on the ANA report. MAINBODY: Sixteen Brazilian researchers and experts from universities and clinical laboratories representing the various geographical regions of Brazil participated in the meeting. Four main topics were discussed: (1) How to classify patterns with fluorescence in more than one cell compartment considering three relevant categoris: composite patterns, mixed patterns and multiple patterns; (2) The splitting of the discrete nuclear dots pattern into the multiple discrete nuclear dots (AC-6) and few discrete nuclear dots (AC-7) patterns, respectively; (3) Inclusion of a novel nuclear pattern characterized by discrete fine speckled pattern highly associated with antibodies to SS-A/Ro60, classified as AC-4a. In addition, adjustments on the Brazilian Consensus nomenclature were implemented aiming to harmonize the designation of some patterns with the International Consensus on ANA Patterns (ICAP). Furthermore, the designations of the PCNA-like pattern (AC-13), CENP-F-like pattern (AC-14) and Topo I-like pattern (AC-29) were adjusted in accordance to ICAP. Finally, there was a recommendation for adjustment in the test report in order to address the status of nuclear envelope staining. For all topics, the aim was to establish specific guidelines for laboratories and clinicians. All recommendations were based on consensus among participants. All recommendations from the V Consensus were maintained and there was relevant progress in the BCA/HEp-2 guidelines and further harmonization with ICAP.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36071498 DOI: 10.1186/s42358-022-00266-z
Source DB: PubMed Journal: Adv Rheumatol ISSN: 2523-3106